Covalent Bioscience
Company focused on healthy aging and age-associated diseases using catalytic antibodies
Covalent Bioscience is the company formed to carry forward work on catalytic antibodies capable of clearing aggregated proteins found in old tissues, such as transthyretin amyloid. This type of amyloid, a misfolded protein that disrupts normal tissue function when present in large enough amounts, is associated with cardiovascular mortality and osteoarthritis, and is thought to be a prevalent cause of death in supercentenarians. The advantage of catalytic antibodies over normal antibodies is that they bind to the target site on a protein, then destroy that site, then move on. One antibody can attack thousands of targets, making low doses potentially highly effective.
Covalent Bioscience is one of a handful of startups and young companies working on science funded in part by the SENS Research Foundation, the foundation for rejuvenation therapies based on repairing and reversing the fundamental cell and tissue damage that causes aging, such as the presence of amyloid.
Visit website: https://covalentbioscience.com/
Details last updated 03-May-2019
Covalent Bioscience is also referenced in the following:
People at Covalent Bioscience
Sudhir Paul
Co-founder and Chief Science Officer at Covalent Bioscience and professor at the University of Nebraska